公开(公告)号：EP2012779B1

公开(公告)日：2012-05-16

申请号：EP07760624.2

申请日：2007-04-13

申请人： ABBOTT LABORATORIES

发明人： LUKIN, Kirill A. ,  CHI-PING HSU, Margaret ,  FERNANDO, Dilinie P. ,  KOTECKI, Brian J. ,  LEANNA, Marvin R.

IPC分类号： A61K31/416 ,  C07D231/56

CPC分类号： C07D231/56

摘要： The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).

公开(公告)号：EP2012779A2

公开(公告)日：2009-01-14

申请号：EP07760624.2

申请日：2007-04-13

申请人： ABBOTT LABORATORIES

发明人： LUKIN, Kirill A. ,  CHI-PING HSU, Margaret ,  FERNANDO, Dilinie P. ,  KOTECKI, Brian J. ,  LEANNA, Marvin R.

IPC分类号： A61K31/416 ,  C07D231/56

CPC分类号： C07D231/56

摘要： The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).

公开(公告)号：EP2203430B1

公开(公告)日：2011-06-15

申请号：EP08831558.5

申请日：2008-09-17

申请人： Abbott Laboratories

发明人： DONNER, Pamela L. ,  RANDOLPH, John T. ,  KRUEGER, Allan C. ,  BETEBENNER, David A. ,  HUTCHINSON, Douglas K. ,  LIU, Dachun ,  LIU, Yaya ,  LONGENECKER, Kenton L. ,  MARING, Clarence J. ,  PRATT, John K. ,  ROCKWAY, Todd W. ,  STEWART, Kent D. ,  WAGNER, Rolf ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  ZHANG, Geoff G. Z.

IPC分类号： C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D239/553 ,  A61K31/513 ,  A61K31/506 ,  A61P31/14

CPC分类号： C07D239/22 ,  A61K31/513 ,  C07D239/54 ,  C07D239/553 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10

摘要： This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I)

公开(公告)号：EP2222646A1

公开(公告)日：2010-09-01

申请号：EP08831873.8

申请日：2008-09-17

申请人： Abbott Laboratories

发明人： WAGNER, Rolf ,  TUFANO, Michael D. ,  STEWART, Kent D. ,  ROCKWAY, Todd W. ,  RANDOLPH, John T. ,  PRATT, John K. ,  MOTTER, Christopher E. ,  MARING, Clarence J. ,  LONGENECKER, Kenton L. ,  LIU, Yaya ,  LIU, Dachun ,  KRUEGER, Allan C. ,  KATI, Warren M. ,  HUTCHINSON, Douglas K. ,  HUANG, Peggy P. ,  FLENTGE, Charles A. ,  DONNER,Pamela L. ,  DEGOEY, David A. ,  BETEBENNER, David A. ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  SARRIS, Kathy ,  ZHANG, Geoff G. Z.

IPC分类号： C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61P31/12 ,  A61K31/513

CPC分类号： A61K31/513 ,  A61K31/5377 ,  C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

摘要： Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.

公开(公告)号：EP2203430A1

公开(公告)日：2010-07-07

申请号：EP08831558.5

申请日：2008-09-17

申请人： Abbott Laboratories

发明人： DONNER, Pamela L. ,  RANDOLPH, John T. ,  KRUEGER, Allan C. ,  BETEBENNER, David A. ,  HUTCHINSON, Douglas K. ,  LIU, Dachun ,  LIU, Yaya ,  LONGENECKER, Kenton L. ,  MARING, Clarence J. ,  PRATT, John K. ,  ROCKWAY, Todd W. ,  STEWART, Kent D. ,  WAGNER, Rolf ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  ZHANG, Geoff G. Z.

IPC分类号： C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D239/553 ,  A61K31/513 ,  A61K31/506 ,  A61P31/14

CPC分类号： C07D239/22 ,  A61K31/513 ,  C07D239/54 ,  C07D239/553 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10

摘要： This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I)